Phase II study of denileukin diftitox (ONTAK) for relapsed/refractory T-cell non-Hodgkin's lymphoma

被引：0
|
作者：
Dang, NH
Pro, B
Fredrick, HR
Samaniego, F
Jones, D
Rodriguez, M
Goy, A
Roaguera, J
Walker, PL
Younes, A
Neelapu, S
Kwak, L
Fayad, L
机构：
[1] Nevada Canc Inst, Las Vegas, NV USA
[2] MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3350
引用
收藏
页码：936A / 936A
页数：1
相关论文
共 50 条
  • [1] Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed/refractory T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Pro, B
    Hagemeister, FB
    Jones, D
    Samuels, B
    Rodriguez, MA
    Goy, A
    Romaguera, JE
    Walker, PL
    Kwak, L
    Fayad, L
    BLOOD, 2004, 104 (11) : 722A - 722A
  • [2] Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Pro, Barbara
    Hagemeister, Fredrick B.
    Samaniego, Felipe
    Jones, Dan
    Samuels, Barry I.
    Rodriguez, Maria A.
    McLaughlin, Peter
    Tong, Ann T.
    Turturro, Francesco
    Walker, Pamela L.
    Fayad, Luis
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (03) : 439 - 447
  • [3] Analysis of a phase II study of denileukin diftitox (ONTAK®) for B and T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Hagemeister, FB
    Fayad, L
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Samaniego, F
    Goy, A
    Wang, M
    Walker, PL
    Samuels, B
    Jones, D
    Rodriguez, MA
    BLOOD, 2003, 102 (11) : 303B - 303B
  • [4] Phase II study of delineukin diftitox (ONTAK®) for relapsed/refractory band T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Hagemeister, FB
    Fayad, L
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Samaniego, F
    Younes, A
    Goy, A
    Preti, A
    Jones, D
    Sarris, A
    East, K
    Rodriguez, MA
    Cabanillas, F
    BLOOD, 2002, 100 (11) : 363A - 363A
  • [5] Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Dang, NH
    Hagemeister, FB
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Jones, D
    Samuels, B
    Samaniego, F
    Younes, A
    Wang, M
    Goy, A
    Rodriguez, MA
    Walker, PL
    Arredondo, Y
    Tong, AT
    Fayad, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) : 4095 - 4102
  • [6] Interim analysis of a phase II study of the combination of denileukin diftitox (Ontak) and rituximab for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
    Dang, NH
    McLaughlin, P
    Fayad, L
    Romaguera, J
    Hagemeister, F
    Younes, A
    Neelapu, S
    Samaniego, F
    Jones, D
    Walker, PL
    Rodriguez, MA
    Kwak, L
    Pro, B
    BLOOD, 2005, 106 (11) : 936A - 936A
  • [7] Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK®)
    Talpur, R
    Apisarnthanarax, N
    Ward, S
    Duvic, M
    LEUKEMIA & LYMPHOMA, 2002, 43 (01) : 121 - 126
  • [8] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Fayad, Luis
    McLaughlin, Peter
    Romaguara, Jorge E.
    Hagemeister, Fredrick
    Goy, Andre
    Neelapu, Sattva
    Samaniego, Felipe
    Walker, Pamela L.
    Wang, Michael
    Rodriguez, Maria A.
    Tong, Ann T.
    Pro, Barbara
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 502 - 505
  • [9] Phase II study of denileukin diftitox (ONTAK®) in patients with relapsed/refractory B-cell Non-Hodgkin's lymphoma (B-NHL) and poor bone marrow reserve.
    Czuczman, Myron S.
    Pinter-Brown, Lauren
    Lechowicz, Mary Jo
    Bartlett, Nancy
    Lazarus, Hillard
    Lister, John
    Goy, Andre
    Kahanic, Stephen
    Rosen, Peter
    Acosta, Mark
    BLOOD, 2006, 108 (11) : 263B - 264B
  • [10] Interleukin 2-based fusion toxin denileukin diftitox for relapsed T-cell non-Hodgkin's lymphomas
    不详
    CLINICAL LYMPHOMA, 2004, 5 (01): : 9 - 10
12345